MHRA approves semaglutide oral tablets for weight loss
Oral semaglutide (Wegovy, Novo Nordisk) tablets for weight loss have been approved by the Medicines and Healthcare products Regulatory Agency (MHRA). In a statement published on 11 June 2026, the MHRA said that the drug — the first oral glucagon-like peptide-1 (GLP-1) available in the UK — can be used in adults with obesity, who have a BMI of 30 or above, or who are overweight with a BMI between 27 and 30 and at least one […]
Read more